This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Palatin Technologies (PTN) in Focus: Stock Moves 5.7% Higher
by Zacks Equity Research
Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.
The Zacks Analyst Blog Highlights: ANI Pharmaceuticals, Avianca, Avid, Terex and Encore Wire
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ANI Pharmaceuticals, Avianca, Avid, Terex and Encore Wire
Fears of Far-Reaching Economic Slowdown Diminish: 5 Picks
by Tirthankar Chakraborty
Encouraging service sector figures from Europe and China, along with increasing optimism in U.S.-China trade negotiations ease fears of a global economic downturn.
5 Stocks With Recent Price Strength Despite Market Volatility
by Nalak Das
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
Moving Average Crossover Alert: ANI Pharmaceuticals
by Zacks Equity Research
ANI Pharmaceuticals, Inc. (ANIP) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
4 Small Biotech Stocks Likely to Witness More Upside in 2019
by Zacks Equity Research
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
New Strong Buy Stocks for March 29th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
All You Need to Know About ANI (ANIP) Rating Upgrade to Strong Buy
by Zacks Equity Research
ANI (ANIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
by Zacks Equity Research
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
New Strong Buy Stocks for March 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Is ANI Pharmaceuticals a Great Stock for Value Investors?
by Zacks Equity Research
Let???s see if ANI Pharmaceuticals (ANIP) stock is a good choice for value-oriented investors right now from multiple angles.
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 5.74% and 0.20%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals (ANIP) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -13.08% and -6.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
by Zacks Equity Research
Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.
Zacks Industry Outlook Highlights: Amgen, ANI and Illumina
by Zacks Equity Research
Zacks Industry Outlook Highlights: Amgen, ANI and Illumina
Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
Biotech Stock Outlook: Short-Term Pricing Pain to Prevail
by Zacks Equity Research
Decline in sales of high-profile drugs, pipeline setbacks and competitive pressure are likely to adversely impact the overall performance of the biotech sector in the short term.
Juniper Inks Deal to be Acquired by Catalent, Shares Up
by Zacks Equity Research
Juniper Pharmaceuticals, Inc. (JNP) inks a deal with Catalent, Inc. Per the deal, Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.
Alkermes' Aristada Initio Approved by FDA for Schizophrenia
by Zacks Equity Research
FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.
Roche's Breast Cancer Study Meets Co-Primary Endpoint
by Zacks Equity Research
Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
Celgene's Luspatercept Meets Primary Endpoint in the Study
by Zacks Equity Research
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announces top-line results from a phase III, multi-center study (MEDALIST), where its pipeline candidate luspatercept met both the primary and secondary endpoints.
Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall
by Zacks Equity Research
Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.
Medicines Company's Inclisiran Studies to Continue Unmodified
by Zacks Equity Research
The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.